Stephan Lensky

Stephan Lensky is Chief Operating and Chief Business Officer of EpimAb.

He joined EpimAb as its first employee in July 2015 and is responsible for EpimAb’s strategy, business development and financing efforts.

Stephan brings more than 15 years of Business Development experience with Pharma to EpimAb. He headed the Corporate Department for Strategic Transactions & Alliance Management at Boehringer Ingelheim GmbH from 2010 until early 2015. His Department was responsible for the negotiation and management of all strategic transactions of Boehringer Ingelheim’s Prescription Medicines (PM) Business and is located in Ingelheim, Germany, with additional groups in Ridgefield, Connecticut, and Tokyo.

Back in 1999, he decided to start a career in business development at Bayer, where he eventually headed a group responsible for all commercial licenses in Europe and the Emerging Markets. In his more than 15 years in business development he conceived, designed, formed and managed a broad variety of partnerships with academia, biotech, big pharma and also generic companies throughout the world.

Stephan holds a Ph.D. in Chemistry and started his professional career in Germany as a medicinal chemist at Bayer where he had been leading various research projects. In 2009, he gained operative commercial experience as the country coordinator for Boehringer Ingelheim’s Prescription Medicines (PM) Business in the United States. Stephan Lensky is a member of the BioFIT Steering Committee since 2014, a conference bringing European Tech Transfer offices, Pharma and Biotech together, and a member of the nanomedTAB, an advisory board for nanotechnology in sponsored by the European Commission.

Stephan Lensky is the COO, CBO at EpimAb Biotherapeutics, based in Europe. With a background in Biotechnology, Stephan Lensky has a rich history of leadership and innovation.Stephan Lensky studied Postdoctoral Fellow Organic Chemistry at University of Notre Dame. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.